Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Earlier this week, Aldeyra Therapeutics, Inc.ALDX announced that it has started patient enrolment in a phase II study on its investigational candidate NS2 for the treatment of Sjögren-Larsson syndrome.

We note that currently NS2 is the only noteworthy candidate in Aldeyra's pipeline and the company is working on the development of this candidate for different indications. Apart from Sjögren-Larsson syndrome, the candidate is being developed for noninfectious anterior uveitis.

Along with the update on the Sjögren-Larsson syndrome study, Aldeyra announced that the FDA has accepted its amended protocol for conducting a phase II study on NS2 for the treatment of noninfectious anterior uveitis. Given the finalization of protocol, Aldeyra expects to start enrolling patients for the study in the first half of 2015. Preliminary data should be out by the end of 2015.

Meanwhile, some other companies are also working for the development of uveitis treatments. AbbVie ABBV is evaluating Humira in several phase III studies for uveitis and intends to file for the drug in the U.S. and the EU in this indication. XOMA Corporation XOMA is also evaluating gevokizumab in three pivotal studies for the treatment of non-infectious intermediate, posterior or pan-uveitis and Behçet's disease uveitis.

Aldeyra carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharmaceutical sector is Lannett Company, Inc. LCI carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

XOMA CORP (XOMA): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report


To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More